ClinicalTrials.gg
RecruitingNCT06052475PROTECT-UPUpdated Jun 23, 2026

Physiological Versus Right Ventricular Outcome Trial Evaluated for Bradycardia Treatment Upgrades

An interventional study of Physiological Pacing Upgrade (Conduction System Pacing or Biventricular Pacing) and Continued RV Pacing (Right Ventricular Pacing) in Pacing-Induced Cardiomyopathy and Heart Failure, sponsored by Imperial College London. Recruiting at 12 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-23.

Sponsored by Imperial College London · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
155
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Heart Failure by Imperial College London — 7 open to participants now, 8 under way, none of them phase 3. Heart Failure · Imperial College London.

Planned enrollment
6th of 18
155 · median 55
Started
2023
with 4 others
No phase
11 of 29
5 open now
Registered
26th of 29
by date

Among the 29 studies in Heart Failure by Imperial College London, this one is the 6th largest by planned enrollment of the 18 interventional ones that give a count, is one of 5 that started in 2023, is one of 11 with no phase, and was the 26th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

7 of the 29 studies in Heart Failure by Imperial College London are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Heart Failure by Imperial College London, or all of them as a file.
02

Study summary

Guidelines for patients having first-time implants advocate that even when heart function is only mildly impaired, modern pacing approaches should be utilised to avoid the potentially damaging effects of RV pacing to preventing symptoms from pacing induced or worsened cardiomyopathy.

However, once a traditional (RV) pacemaker is implanted, development of impaired heart function does not prompt a device upgrade. Even at the end of battery life, physicians simply replace it like-for-like.

This trial tests whether such patients have better symptoms and quality of life if changed to a modern physiological pacing strategy from the traditional RV pacing approach.

In this crossover trial, participants will be upgraded to a physiological pacing strategy.

After their procedure, they will have a one-month run-in period to recover from the procedure (their pacemaker will be programmed to continued RV pacing).

They will be have 2 one-month blinded time periods, randomised to physiological pacing or right ventricular pacing alternately. They will subsequently undergo two six-month blinded randomised time periods.

Patients will document symptoms monthly on a mobile phone application or computer. At the end of each time period, they will have measurements of heart function, a walking test and quality-of-life questionnaires including the SF-36 questionnaire.

The investigators hypothesise that upgrading to physiological pacing strategies will improve patients' quality of life.

03

Conditions studied

  • Pacing-Induced Cardiomyopathy
  • Heart Failure

Browse trials for

Keywords

  • Physiological Pacing
  • RV Pacing
  • Biventricular Pacing
  • Pacemaker Upgrade
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Patients with an RV pacemaker and 35-50% and a high burden of right ventricular pacing (>40%) who are clinically indicated for a cardiac resynchronisation therapy upgrade procedure and:

  1. EF reduced by >5% of increase in LVESV by 10ml since implant
  2. NT-proBNP >250ng/L in sinus rhythm
  3. NT-proBNP > 750 Ng/L if AF
  4. Left atrial volume index > 30ml/m2
  5. Regular loop diuretics prescribed
  6. Decline in daily patient activity by >1 hour per day since implant
  7. Decrease in device measured thoracic impedance
  8. Patient reported decline in functional class or exercise tolerance

Exclusion Criteria:

  • Those unable to provide
  • Patients under age 18
  • Pregnant women
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
155 participants (estimated)

Study arms

  • Experimental
    Physiological Pacing (Conduction System Pacing or Biventricular Pacing)

    The approach for physiological pacing will be either His bundle pacing or left bundle pacing at the operator's discretion. If both of these are not achieved biventricular pacing will be performed.

    Device: Physiological Pacing Upgrade (Conduction System Pacing or Biventricular Pacing)

  • Active comparator
    Right Ventricular Pacing

    Right ventricular pacing (apical or septal lead locations as per the implanting physicians' normal practice)

    Device: Continued RV Pacing (Right Ventricular Pacing)

Interventions

  • DevicePhysiological Pacing Upgrade (Conduction System Pacing or Biventricular Pacing)

    The approach for physiological pacing upgrade will be either His bundle pacing or left bundle pacing at the operator's discretion. If both of these are not achieved biventricular pacing will be performed.

  • DeviceContinued RV Pacing (Right Ventricular Pacing)

    Right ventricular pacing (apical or septal lead locations as per the implanting physicians' normal practice).

06

What researchers measure

Primary outcomes

  1. SF-36 (Short Form 36 Health Survey Questionnaire) Physical Component Summary

    Time frame: From date of baseline, until end of trial follow-up at fourteen months post-baseline

Secondary outcomes

  1. Left ventricular ejection fraction

    (% ejection fraction)

    Time frame: From date of baseline, until end of trial follow-up at fourteen months

  2. Left ventricular end systolic volume

    (millilitres)

    Time frame: From date of baseline, until end of trial follow-up at fourteen months

  3. Minnesota Living with Heart Failure Questionnaire

    Time frame: From date of baseline, until end of trial follow-up at fourteen months

  4. Six-minute walk test

    Measured in distance in metres

    Time frame: From date of baseline, until end of trial follow-up at fourteen months

  5. Atrial fibrillation

    (atrial fibrillation percentage burden as measured by pacemaker device - %)

    Time frame: From date of baseline, until end of trial follow-up at fourteen months

  6. Patient preference based on blinded symptomatic preference

    Time frame: At 2 months following baseline and 14 months following baseline visit

  7. EQ-5D Questionnaire

    EQ-5D is the name of the instrument and is not an acronym. The EQ-5D-5L consists of 2 pages: the EQ-5D descriptive system and the EQ 'visual analogue scale' (EQ VAS). The descriptive system is made up of 5 sections: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative (numerical) measure of health outcome that reflect the patient's own judgement. A high score on the VAS means a better outcome. A low score on the VAS means a worse outcome.

    Time frame: From date of baseline, until end of trial follow-up at fourteen months post-baseline visit

  8. Patient symptoms assessed on a scale of 0-100 monthly

    This questionnaire will be sent to participants on a monthly basis for the duration of the study

    Time frame: From date of baseline, until end of trial follow-up at fourteen months post-baseline visit

  9. Safety endpoints

    Device infections (requiring device extraction), pacing thresholds, need for lead revision or reimplantation, generator change, haematoma and pneumothorax

    Time frame: From device implant date, assessed up to 15 months at the end of the trial (including a one-month run-in period post-procedure prior to the first baseline visit)

  10. SF-36 (Short Form 36 Health Survey Questionnaire) Overall Score

    Time frame: From date of baseline, until end of trial follow-up at fourteen months post baseline visit

  11. SF-36 (Short Form 36 Health Survey Questionnaire) Individual Component Scores

    Time frame: From date of baseline, until end of trial follow-up at fourteen months post baseline visit

  12. BNP (B-type natriuretic peptide)

    B-type natriuretic peptide blood test

    Time frame: From date of baseline, until end of trial follow-up at fourteen months post baseline visit

07

Study locations

12 of 12 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Sep 2026, 36 months after the start.

Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 36 months is above that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2023
First posted
Sep 25, 2023
StartActual
Sep 4, 2023
Primary completionEst.
Sep 30, 2026
CompletionEst.
Sep 4, 2027
Last update
Jun 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06052475
Responsible party
Sponsor
First posted
Sep 25, 2023
Start date
Sep 4, 2023
Primary completion
Sep 30, 2026 (estimated)
Completion
Sep 4, 2027 (estimated)
Last update
Jun 23, 2026

Study contacts

Aya Khalil
Contact
a.khalil@imperial.ac.uk
07749576830
Nandita Kaza, MRCP
Contact
n.kaza@imperial.ac.uk
07749576830
Daniel Keene, PhD
principal investigator · Imperial College London
Nandita Kaza, MRCP
study director · Imperial College London
Matthew Shun-Shin, PhD
study director · Imperial College London

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion